IMMX logo

Immix Biopharma, Inc. Common Stock


IMMX: Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.


Show IMMX Financials

Consumer Interest
SEC Filings

Recent trades of IMMX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by IMMX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cancer therapeutics Dec. 05, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of IMMX in WallStreetBets Daily Discussion


Recent insights relating to IMMX

CNBC Recommendations

Recent picks made for IMMX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IMMX

Corporate Flights

Flights by private jets registered to IMMX